complications of combined treatment with deferiprone and desferrioxamine in thalassemic patients
نویسندگان
چکیده
although successful iron chelation with deferiprone is associated with significant complications, patient’s compliance with medication regimens is of a high priority. the present study did evaluate the complications and compliance of domestically-manufactured deferiprone combined with desferrioxamine for iron chelation therapy. a total of 32 major beta thalassemic patients with cardiomyopathy were enrolled in the study and were monitored clinically and paraclinically. upon every visit, the patients were prescribed only the number of tablets deemed necessary. the side effects observed as nausea (25%), vomiting (12%), neutropenia (12%), thrombocytopenia (6%), and joint pain (3%) without agranulocytosis or increased liver enzymes to more than twice the normal values. deferiprone was discontinued in 30% of patients because of severe refractory gastrointestinal complaints (12%), recurrent neutropenia (6%), recurrent thrombocytopenia (6%), severe arthropathy (3%), or interferon therapy (3%). none of the patients, except one, remembered taking full number of the prescribed tablets. twenty seven patients used 35% to 92% of the prescribed tablets. poor compliance with deferiprone due to patient’s neglect to take the drug 3 times a day for a prolonged period was the main problem in this regimen. although thrombocytopenia was more common compared with those of previous reports, other complications were seen with equal or lower frequencies. this study shows that a lower daily dose is the most favorable property of an oral iron chelator for prolonged usage.
منابع مشابه
Complications of Combined Treatment with Deferiprone and Desferrioxamine in Thalassemic Patients
Although successful iron chelation with deferiprone is associated with significant complications, patient’s compliance with medication regimens is of a high priority. The present study did evaluate the complications and compliance of domestically-manufactured deferiprone combined with desferrioxamine for iron chelation therapy. A total of 32 major beta thalassemic patients with cardiomyopathy w...
متن کاملCombined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Sanna Kotisaari,* Jarkko Romppanen,* Ulla Ågren,° Sakari Eskelinen,* Kari Punnonen* *Department of Clinical Chemistry, Kuopio University Hospital, PL 1777, Kuopio; °Students’ Health Service, Kuopio University, PL 1777, 70211 Kuopio, Finland
متن کاملCombined therapy with deferiprone and desferrioxamine in thalassemia major.
BACKGROUND AND OBJECTIVES Effective and convenient iron chelation remains one of the main targets of clinical management of thalassemia major. The combined treatment with desferrioxamine and deferiprone could have an increased chelation efficacy and sometimes allow drug doses and toxicity to be reduced and the number of days of desferrioxamine infusion to be decreased, improving compliance and ...
متن کاملmodern surgical techniques in treatment of patients with cleft lip & cleft palate
چکیده ندارد.
15 صفحه اولCombined Therapy with Deferiprone and Desferrioxamine as Compared to Desferasirox on Ventricular Function in Thalassemia Major Patients
Abstract Background Myocardial iron overload is the leading cause of death in patients with beta-thalassemia major. Combined therapy with deferiprone(DFP) and desferrioxamine (DFO)were suggested to be more effective than deferasirox(DFX) for removing heart iron. Deferasirox has recently been made available, but its long-term efficacy on cardiac function has not yet been established. Our study...
متن کاملComparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children.
OBJECTIVE Ascertainment of an appropriate strategy of iron chelation for multi-transfused thalassemic children in developing countries. DESIGN Prospective study from May 2000 to April 2001. SETTING Urban tertiary care center. METHODS Thirty thalassemic children having received more than 20 blood transfusions and a serum ferritin greater than 1500 ng/ml were enrolled and randomized into th...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
iranian journal of medical sciencesجلد ۳۳، شماره ۱، صفحات ۴۰-۰
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023